インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections):治療薬開発パイプライン動向(2014年下半期版)

◆英語タイトル:Haemophilus Influenzae Type b Infections - Pipeline Review, H2 2014
◆商品コード:GMDHC5693IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2014年11月18日
◆ページ数:68
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥208,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥624,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、世界におけるインフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)の概要
・インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Haemophilus Influenzae Type b Infections – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Haemophilus Influenzae Type b Infections – Pipeline Review, H2 2014’, provides an overview of the Haemophilus Influenzae Type b Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Haemophilus Influenzae Type b Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Haemophilus Influenzae Type b Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Haemophilus Influenzae Type b Infections
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Haemophilus Influenzae Type b Infections and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Haemophilus Influenzae Type b Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Haemophilus Influenzae Type b Infections pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Haemophilus Influenzae Type b Infections
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Haemophilus Influenzae Type b Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Haemophilus Influenzae Type b Infections Overview 8
Therapeutics Development 9
Pipeline Products for Haemophilus Influenzae Type b Infections – Overview 9
Pipeline Products for Haemophilus Influenzae Type b Infections – Comparative Analysis 10
Haemophilus Influenzae Type b Infections – Therapeutics under Development by Companies 11
Haemophilus Influenzae Type b Infections – Therapeutics under Investigation by Universities/Institutes 13
Haemophilus Influenzae Type b Infections – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Unknown Stage Products 17
Haemophilus Influenzae Type b Infections – Products under Development by Companies 18
Haemophilus Influenzae Type b Infections – Products under Investigation by Universities/Institutes 20
Haemophilus Influenzae Type b Infections – Companies Involved in Therapeutics Development 21
Beijing Minhai Biotechnology Co., Ltd 21
Biological E. Limited 22
Chongqing Zhifei Biological Products Co., Ltd. 23
GlaxoSmithKline plc 24
Indian Immunologicals Limited 25
LG Life Sciences, Ltd. 26
Novartis AG 27
Nuron Biotech, Inc. 28
Panacea Biotec Limited 29
Sanofi Pasteur SA 30
Sinovac Biotech Ltd. 31
Zydus Cadila Healthcare Limited 32
Haemophilus Influenzae Type b Infections – Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Combination Products 34
Assessment by Target 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
GSK-217744 – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
haemophilus influenza [serotype B] vaccine – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
haemophilus influenzae [serotype B] + meningococcal polysaccharide [serotypes A, C, Y, W-135] vaccine – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
haemophilus influenzae [serotype B] vaccine – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
haemophilus influenzae [type B] vaccine – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
haemophilus influenzae conjugate vaccine [type B] – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
haemophilus influenzae type b oligosaccharide conjugate vaccine – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
haemophilus influenzae vaccine [type B] – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
hemophilus influenza [Type B] vaccine – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
NU-300 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Vaccine for Haemophilus Influenzae Type b Infections – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Haemophilus Influenzae Type b Infections – Recent Pipeline Updates 60
Haemophilus Influenzae Type b Infections – Dormant Projects 62
Haemophilus Influenzae Type b Infections – Product Development Milestones 63
Featured News & Press Releases 63
Oct 20, 2014: US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur’s Investigational Pediatric Hexavalent Vaccine 63
Sep 26, 2013: Takeda Submits New Drug Application in Japan for TAK-816, a Haemophilus Influenzae type b vaccine 64
Apr 22, 2013: Sanofi Obtains European Approval For Six-in-One Pediatric Vaccine Hexyon/Hexacima 64
Feb 22, 2013: Sanofi Pasteur Announces EMA’s CHMP Recommends Approval Of Hexyon/Hexacima Six-In-One Pediatric Vaccine 65
Oct 19, 2012: Sanofi Pasteur To Commercialize New 6-in-1 Paediatric Vaccine In European Markets 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 68
Disclaimer 68

[List of Tables]
Number of Products under Development for Haemophilus Influenzae Type b Infections, H2 2014 9
Number of Products under Development for Haemophilus Influenzae Type b Infections - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 12
Number of Products under Investigation by Universities/Institutes, H2 2014 13
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Development, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Products under Development by Companies, H2 2014 18
Products under Investigation by Universities/Institutes, H2 2014 20
Haemophilus Influenzae Type b Infections - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 21
Haemophilus Influenzae Type b Infections - Pipeline by Biological E. Limited, H2 2014 22
Haemophilus Influenzae Type b Infections - Pipeline by Chongqing Zhifei Biological Products Co., Ltd., H2 2014 23
Haemophilus Influenzae Type b Infections - Pipeline by GlaxoSmithKline plc, H2 2014 24
Haemophilus Influenzae Type b Infections - Pipeline by Indian Immunologicals Limited, H2 2014 25
Haemophilus Influenzae Type b Infections - Pipeline by LG Life Sciences, Ltd., H2 2014 26
Haemophilus Influenzae Type b Infections - Pipeline by Novartis AG, H2 2014 27
Haemophilus Influenzae Type b Infections - Pipeline by Nuron Biotech, Inc., H2 2014 28
Haemophilus Influenzae Type b Infections - Pipeline by Panacea Biotec Limited, H2 2014 29
Haemophilus Influenzae Type b Infections - Pipeline by Sanofi Pasteur SA, H2 2014 30
Haemophilus Influenzae Type b Infections - Pipeline by Sinovac Biotech Ltd., H2 2014 31
Haemophilus Influenzae Type b Infections - Pipeline by Zydus Cadila Healthcare Limited, H2 2014 32
Assessment by Monotherapy Products, H2 2014 33
Assessment by Combination Products, H2 2014 34
Number of Products by Stage and Target, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Haemophilus Influenzae Type b Infections Therapeutics - Recent Pipeline Updates, H2 2014 60
Haemophilus Influenzae Type b Infections - Dormant Projects, H2 2014 62

[List of Figures]
Number of Products under Development for Haemophilus Influenzae Type b Infections, H2 2014 9
Number of Products under Development for Haemophilus Influenzae Type b Infections - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 14
Comparative Analysis by Clinical Stage Development, H2 2014 15
Comparative Analysis by Early Stage Products, H2 2014 16
Comparative Analysis by Unknown Stage Development, H2 2014 17
Assessment by Monotherapy Products, H2 2014 33
Assessment by Combination Products, H2 2014 34
Number of Products by Top 10 Targets, H2 2014 35
Number of Products by Stage and Top 10 Targets, H2 2014 36
Number of Products by Top 10 Routes of Administration, H2 2014 37
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 38
Number of Products by Top 10 Molecule Types, H2 2014 39
Number of Products by Stage and Top 10 Molecule Types, H2 2014 40

【掲載企業】

Beijing Minhai Biotechnology Co., Ltd
Biological E. Limited
Chongqing Zhifei Biological Products Co., Ltd.
GlaxoSmithKline plc
Indian Immunologicals Limited
LG Life Sciences, Ltd.
Novartis AG
Nuron Biotech, Inc.
Panacea Biotec Limited
Sanofi Pasteur SA
Sinovac Biotech Ltd.
Zydus Cadila Healthcare Limited

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[インフルエンザ菌B型感染症(Haemophilus Influenzae Type b Infections):治療薬開発パイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆